Claims for Patent: 8,956,600

Summary for Patent: 8,956,600

Title:	Ophthalmic drug delivery system containing phospholipid and cholesterol
Abstract:	An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
Inventor(s):	Shih; Sheue-Fang (Taipei, TW), Chang; Po-Chun (Taipei, TW), Tseng; Yun-Long (Taipei, TW), Guo; Luke S. S. (South San Francisco, CA), Hong; Keelung (South San Francisco, CA)
Assignee:	Taiwan Liposome Co. Ltd. (Taipei, TW) TLC Biopharmaceuticals, Inc. (South San Francisco, CA)
Application Number:	12/538,435
Patent Claims:	1. An ophthalmic drug delivery system, comprising (a) a delivery vehicle suitable for vitreous humor drug delivery consisting essentially of a phospholipid or a mixture of phospholipids selected from the group consisting of DOPC, POPC, SPC, EPC, PEG-DSPE and DOPG and cholesterol, wherein cholesterol is present in an amount of 10-33 mole percent relative to the delivery vehicle; and (b) an antagonist specific to VEGF selected from a group consisting of an antibody specific to VEGF, a VEGF receptor, a nucleic acid or a small molecule; wherein 50-90% of the antagonist is in non-associated form, the weight ratio of the phospholipid and cholesterol in combination to the antagonist is 5-80 to 1 and the life time of the antagonist is extended in the vitreous humor. 2. The ophthalmic drug delivery system of claim 1, wherein the antibody specific to VEGF is a naturally occurring immunoglobulin, a functional fragment thereof, a humanized antibody, a chimeric antibody, a diabody or a single chain antibody. 3. The ophthalmic drug delivery system of claim 1, wherein the antibody specific to VEGF is Avastin. 4. The ophthalmic drug delivery system of claim 1, wherein the antibody is a Fab, Fab', F(ab).sub.2 or F(ab').sub.2 fragment. 5. The ophthalmic drug delivery system of claim 1, wherein the phospholipid is a mixture of a first phospholipid and a second phospholipid, the first phospholipid being DOPC, POPC, SPC, or EPC and the second phospholipid being PEG-DSPE or DOPG. 6. The ophthalmic drug delivery system of claim 5, wherein the first phospholipid is DOPC and the second phospholipid is DOPG. 7. The ophthalmic drug delivery system of claim 6, wherein, in the delivery vehicle, the mole percent of DOPC is 29.5% to 90%, the mole percent of DOPG is 3% to 37.5%. 8. The ophthalmic drug deliver system of claim 6, wherein the ratio of DOPC:DOPG:cholesterol is 56.25-72.5:7.5-18.75:20-25 by mole percent. 9. The ophthalmic drug delivery system of claim 7, wherein the antagonist specific to VEGF is Avastin. 10. The ophthalmic drug delivery system of claim 8, wherein the antagonist specific to VEGF is Avastin. 11. The ophthalmic drug delivery system of claim 9, wherein 60-90% of the antagonist is in non-associated form and the weight ratio of the phospholipid and cholesterol in combination to the antagonist is 5-40 to 1. 12. The ophthalmic drug delivery system of claim 10, wherein 60-90% of the antagonist is in non-associated form and the weight ratio of the phospholipid and cholesterol in combination to the antagonist is 5-40 to 1. 13. The ophthalmic drug delivery system of claim 1, further comprising an anti-inflammation molecule. 14. The ophthalmic drug delivery system of claim 13, wherein the anti-inflammation molecule is a corticosteroid. 15. The ophthalmic drug delivery system of claim 14, wherein the corticosteroid is selected from the group consisting of cortisone, hydrocortisone, fluocinolone, prednisolone, prednisone, triamcinolone, methylprednisolone, dexamethasone, and betamethasone. 16. The ophthalmic drug delivery system of claim 1, wherein the delivery vehicle and the antagonist are admixed and in lyophilized form. 17. The ophthalmic drug delivery system of claim 1, wherein the delivery vehicle and the antagonist are separate. 18. The ophthalmic drug delivery system of claim 17, wherein the delivery vehicle is in lyophilized form. 19. A drug delivery system, comprising (a) a delivery vehicle suitable for vitreous humor drug delivery consists essentially of a phospholipid or a mixture of phospholipids selected from the group consisting of DOPC, POPC, SPC, EPC, PEG-DSPE and DOPG, and cholesterol, wherein cholesterol is present in an amount of 10-33 mole percent relative to the delivery vehicle; and (b) one or more therapeutic agents to the eye; wherein 50-90% of the therapeutic agent to the eye is in non-associated form, the weight ratio of the phospholipid and cholesterol in combination to the therapeutic agent to the eye is 5-80 to 1 and the life time of the therapeutic agent is extended in the vitreous humor. 20. The drug delivery system of claim 19, wherein the therapeutic agent to the eye is an antagonist specific to VEGF. 21. The drug delivery system of claim 20, wherein the antagonist specific to VEGF is an antibody specific to VEGF, a VEGF receptor, a nucleic acid or a small molecule. 22. The drug delivery system of claim 20, wherein the antibody specific to VEGF is a naturally occurring immunoglobulin, a functional fragment thereof, a humanized antibody, a chimeric antibody, a diabody or a single chain antibody. 23. The drug delivery system of claim 20, wherein, the antibody specific to VEGF is Avastin. 24. The drug delivery system of claim 20, wherein the antibody specific to VEGF is a Fab, Fab', F(ab).sub.2 or F(ab').sub.2 fragment. 25. The drug delivery system of claim 19, wherein the therapeutic agent to the eye is an anti-inflammation molecule. 26. The drug delivery system of claim 25, wherein the anti-inflammation molecule is a corticosteroid. 27. The drug delivery system of claim 19, wherein the delivery vehicle and the therapeutic agent to the eye are admixed and in lyophilized form. 28. The drug delivery system of claim 19 wherein the delivery vehicle and the therapeutic agent to the eye are separate. 29. The drug delivery system of claim 28, wherein the delivery vehicle is in lyophilized form. 30. The drug delivery system of claim 19, wherein the phospholipid is a mixture of a first phospholipid and a second phospholipid, the first phospholipid being DOPC, POPC, SPC, or EPC and the second phospholipid being PEG-DSPE or DOPG. 31. The drug delivery system of claim 30, wherein the first phospholipid is DOPC and the second phospholipid is DOPG. 32. The drug delivery system of claim 31, wherein, in the delivery vehicle, the mole percent of DOPC is 29.5% to 90%, the mole percent of DOPG is 3% to 37.5%. 33. The drug deliver system of claim 31, wherein the ratio of DOPC:DOPG:cholesterol is 56.25-72.5:7.5-18.75:20-25 by mole percent. 34. The drug delivery system of claim 32, wherein 60-90% of the therapeutic agent to the eye is in non-associated form and the weight ratio of the phospholipid and cholesterol in combination to the therapeutic agent to the eye is 5-40 to 1. 35. The drug delivery system of claim 33, wherein 60-90% of the therapeutic agent to the eye is in non-associated form and the weight ratio of the phospholipid and cholesterol in combination to the therapeutic agent to the eye is 5-40 to 1. 36. The ophthalmic drug delivery system of claim 1, wherein the cholesterol is present in an amount of 25 mole percent relative to the delivery vehicle. 37. The drug delivery system of claim 19, wherein the cholesterol is present in an amount of 25 mole percent relative to the delivery vehicle. 38. The drug delivery system of claim 26, wherein the corticosteroid is selected from the group consisting of cortisone, hydrocortisone, fluocinolone, prednisolone, prednisone, triamcinolone, methylprednisolone, dexamethasone, and betamethasone.

Details for Patent 8,956,600

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2039-02-26